API
< Back to all clusters
[BUSINESS] · India, United States, China, Germany · 3 sources

started · updated

Sun Pharma secures global rights for cholesterol drug lerodalcibep

Sun Pharmaceutical Industries Ltd has signed an exclusive global licensing, commercialization, and manufacturing agreement with LIB Therapeutics Inc for the cholesterol-lowering drug lerodalcibep. Under the terms of the deal, Sun Pharma holds the rights to the drug in all markets except for the United States and China.

Lerodalcibep is a PCSK9 inhibitor administered as a 300 mg monthly subcutaneous injection to treat adults with high cholesterol and mixed dyslipidemia. The drug, which is marketed as Lyrokaul in the European Union, recently received EU approval on September 21, 2026. A notable feature of the medication is its stability, allowing it to be stored at room temperature for up to six months once removed from refrigeration in the EU.

As part of the agreement, Sun Pharma will manage regulatory approvals in territories where the drug is not yet cleared. LIB Therapeutics will receive an upfront payment, milestone payments, and royalties based on net sales, though specific financial details remain confidential.

Entities

LIB Therapeutics Inc · Lerodalcibep · Sun Pharmaceutical Industries Ltd